This fact sheet is for men who have been offered chemotherapy to treat their prostate cancer. We describe how chemotherapy can be used to treat prostate cancer, as well as the possible side effects.

References  

Updated: Jan 2014 | Due for Review: Jan 2016

  • Bahl A, Oudard S, Tombal B, Özgürog^lu M, Hansen S, et al, for the TROPIC Investigators. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. 2013: Annals of Oncology 00: 1–7
  • Collins R, Trowman R, Norman G, et al. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Br J Cancer. 2006 Aug 21;95(4):457-62
  • Colloca G, Venturino A, Checcaglini F. Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review. Cancer Treat Rev. 2010 Oct;36(6):501-6. Epub 2010 Feb 23
  • De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet 201;376:1147- 1154
  • Doyle-Lindrud S. Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer. [Review] Clinical Journal of Oncology Nursing.  16(3):286-91, 2012 Jun 1
  • EAU Prostate cancer guidelines - Update March 2013
  • Husson O, Mols F & van de Poll-Franse LV. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Annals of Oncology. 2011;22(4):761-72
  • National Cancer Drugs Fund List June 2013 http://www.england.nhs.uk/wp-content/uploads/2013/06/ncdf-list1.pdf
  • NICE Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen TA259
  • NICE Prostate cancer: diagnosis and treatment. Clinical guideline. 2008. Available from: http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11924
  • Papandreou CN, Daliani DD, Thall PF, Tu S-M, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002 Jul 15;20(14):3072–80
  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ et al. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med 2013;368:138-48. http://www.england.nhs.uk/wp-content/uploads/2013/06/ncdf-list1.pdf
  • Serpa Neto A.  Tobias-Machado M.  Kaliks R.  Wroclawski ML.  Pompeo AC.  Del Giglio A. Ten years of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and meta-analysis of 2244 patients in 12 randomized clinical trials. [Review] Clinical Genitourinary Cancer.  9(2):115-23, 2011 Dec. [Journal Article.  Meta-Analysis.  Review]
  • Singer EA.  Srinivasan R. Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events. Urologic Oncology.  30(4 Suppl):S15-9, 2012 Jul-Aug
  • Tipton JM, McDaniel RW, Barbour L, Johnston MP, Kayne M, LeRoy P, Ripple ML. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2007 Feb;11(1):69-78

About this publication  

This fact sheet is for men who have been offered chemotherapy to treat their prostate cancer. We describe how chemotherapy can be used to treat prostate cancer, as well as the possible side effects.

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.

Download digital versions of this publication